Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)

The summary for the Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01): The purpose of this Funding Opportunity Announcement (FOA) is to continue funding for early development clinical trials of investigational new anticancer drugs sponsored by the NCI Cancer Therapy Evaluation Program (CTEP). The NCI solicits applications from established centers with clinical and scientific experience and patient resources to perform Phase 1 single agent clinical trials, Phase 1 agent combination clinical trials, limited Phase 2 clinical trials, and pilot clinical trials of novel anticancer agents. In addition to the clinical evaluation of new agents, the objectives include the characterization of the effects of these agents on their targets. This objective is to be addressed through the integration of suitable biochemical, pathological, immunological, molecular, and/or imaging methods and correlating the effects of the agents with clinically relevant endpoints.

Federal Grant Title:	Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-07-031
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Cancer Treatment Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Mar 27, 2007
Posted Date:	Dec 12, 2006
Creation Date:	Dec 12, 2006
Archive Date:	Apr 26, 2007
Total Program Funding:	$8,260,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	14
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education For profit organizations other than small businesses Small businesses
Additional Information on Eligibility: Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Only U.S. and Canadian institutions (*) are eligible to apply. Other Foreign institutions may participate in the program through collaborations with U.S. and/or Canadian applicant organizations.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...